A new study reported in the March 11 2004 issue of the New England Journal of Medicine shows benefits of switching from tamoxifen to Aromasin (chemical name: exemestane) for post-menopausal women with early-stage hormone-receptor-positive disease. This study adds to the growing body of evidence that aromatase inhibitors (i.e. Arimidex Femara and Aromasin) seem to prevent breast cancer recurrence better than tamoxifen.

Warmest regards

Paul